Prime Medicine, Inc. (PRME) Stock Forecast 2026: P10, P50 & P90 — Probabli.AI
Timestamped PRME stock forecast with 1-year P10, P50, and P90 price estimates, scenario probabilities, definitions, sources, and limitations.
Direct answer: Prime Medicine, Inc. is positioned as an innovative leader in the gene editing and gene therapy field with high potential upside due to its groundbreaking technology and strong strategic initiatives. However, risks related to clinical results, regulatory hurdles, and market acceptance should not be overlooked. The positive analyst consensus coupled with recent funding rounds and partnerships supports a bullish outlook especially for long-term investors. The saved 1-year distribution is P10 $2.8, P50 $6.2, and P90 $8.5.
Last analyzed · Model: gpt-4o
Prime Medicine, Inc. Forecast data
| Estimate | 1-year price | Meaning |
|---|
| P10 | $2.8 | Pessimistic plausible scenario |
| P50 | $6.2 | Median scenario |
| P90 | $8.5 | Optimistic plausible scenario |
What the numbers mean
P10, P50, and P90 are model-generated scenario estimates: roughly a pessimistic plausible outcome, a median outcome, and an optimistic plausible outcome. They are not calibrated confidence intervals.
Supporting analysis
Prime Medicine's focus on breakthrough technology in gene editing and its ability to secure significant funding rounds position it for strong potential returns within the near term. Analyst targets suggest substantial upside potential, though execution risks remain.
Sources and limitations
Market and company inputs are primarily sourced through Yahoo Finance and public financial-data interfaces. This page reports a saved AI-generated scenario analysis as of the timestamp above; it is not live data, audited probability, financial advice, or a guaranteed return.
Frequently asked questions
When was this PRME analysis generated?
April 11, 2026.
Is this a guaranteed PRME prediction?
No. It is a model-generated scenario assessment with material uncertainty.
View the full PRME stock analysis · PRME sentiment · Methodology · Accuracy & validation
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.